CRH (CRH) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
30 Jul, 2026Executive summary
Achieved record Q2 2026 results with revenues of $10.8 billion, up 6% year-over-year, driven by strong demand, positive pricing, disciplined execution, and contributions from acquisitions.
Net income rose 13% to $1.5 billion, supported by operating performance and divestiture gains.
Completed 17 acquisitions YTD ($1.4 billion), including a definitive agreement to acquire Arcosa for $8.5 billion, reinforcing North American aggregates and infrastructure leadership.
Executed major divestitures totaling $1.9 billion, reallocating capital to higher-growth businesses.
Maintained active capital allocation with increased dividends and paused share buybacks post-Arcosa announcement.
Financial highlights
Q2 revenues reached $10.8 billion (+6% YoY); Adjusted EBITDA $2.63 billion (+7% YoY); net income $1.5 billion (+13% YoY); diluted EPS $2.21 (+14% YoY).
Adjusted EBITDA margin improved to 24.4% (+30bps YoY); net income margin 14.0% (+90bps YoY).
Depreciation, depletion, and amortization charges increased to $548 million due to acquisitions.
Interest expense rose to $220 million from higher gross debt; interest income declined to $22 million.
Other nonoperating income was $282 million, mainly from divestiture gains.
Outlook and guidance
Reaffirmed FY26 guidance: Adjusted EBITDA $8.1–$8.5 billion, net income $3.9–$4.1 billion, diluted EPS $5.60–$6.05.
Capital expenditure guidance updated to $2.7–$2.9 billion for 2026.
Positive demand outlook, especially in infrastructure and reindustrialization, with strong backlogs and bidding activity.
Expects continued margin expansion and robust performance into 2027.
2030 targets: 7–9% annual revenue growth, Adjusted EBITDA margin 22–24%, and Adjusted FCF conversion >100%.
Latest events from CRH
- Strong organic profit growth and cash generation cut year-end net debt below 3x EBITDA.CRH
H2 2015 - Strong growth and cash generation cut leverage to 1.7x while supporting further growth.CRH
H2 2016 - €3.3bn EBITDA, stronger margins and returns, and major acquisitions positioned for further growth.CRH
H2 2017 - U.S. momentum and cost actions supported 2013 progress as net debt fell EUR 519m.CRH
H2 2012 - H2 momentum improved as portfolio actions and disciplined investment set up a moderate 2014 recovery.CRH
H2 2013 - EBITDA rose 11% in 2014; 2015 priorities were growth, integration and debt reduction.CRH
H2 2014 - Sales rose 5% and EBITDA reached €1.66bn as margins proved resilient.CRH
H2 2011 - Cash discipline and cost savings steadied results as markets began to stabilize.CRH
H2 2010 - Q3 EBITDA held near prior year; FY26 guidance is $7.8B–$8.0B amid cost and residential headwinds.CRH
Q3 2026